GAIL HARRISON to Ganciclovir
This is a "connection" page, showing publications GAIL HARRISON has written about Ganciclovir.
Connection Strength
0.978
-
Oral Valganciclovir Initiated Beyond 1 Month of Age as Treatment of Sensorineural Hearing Loss Caused by Congenital Cytomegalovirus Infection: A Randomized Clinical Trial. J Pediatr. 2024 May; 268:113934.
Score: 0.222
-
Congenital cytomegalovirus infection treatment. Pediatr Infect Dis J. 2003 Nov; 22(11):1005-6.
Score: 0.218
-
Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital cytomegalovirus infections involving the central nervous system. J Clin Virol. 2009 Dec; 46 Suppl 4:S22-6.
Score: 0.164
-
Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr. 2003 Jul; 143(1):16-25.
Score: 0.107
-
Progressive, Long-Term Hearing Loss in Congenital CMV Disease After Ganciclovir Therapy. J Pediatric Infect Dis Soc. 2022 Jan 27; 11(1):16-23.
Score: 0.097
-
Successful treatment with oral valganciclovir of primary CMV enterocolitis in a congenitally infected infant. Fetal Pediatr Pathol. 2011; 30(6):437-41.
Score: 0.094
-
Epidemiology and long-term outcomes of cytomegalovirus DNAemia and disease in pediatric solid organ transplant recipients. Am J Transplant. 2022 01; 22(1):187-198.
Score: 0.047
-
Detection of cytomegalovirus (CMV) DNA by polymerase chain reaction is associated with hearing loss in newborns with symptomatic congenital CMV infection involving the central nervous system. J Infect Dis. 2005 Jan 15; 191(2):227-33.
Score: 0.029